Prism Medico & Pharmacy Ltd

Prism Medico & Pharmacy Ltd has reached a significant milestone by hitting a new 52-week high of Rs.28.79, marking a continuation of its robust upward momentum in the Non Banking Financial Company (NBFC) sector. This achievement reflects a remarkable rally over the past nine trading sessions, with the stock delivering substantial returns well above sector and benchmark indices.

Prism Medico & Pharmacy Ltd has surged to a fresh 52-week high of Rs.27.42, marking a significant milestone in its stock performance. This new peak reflects sustained momentum, with the stock demonstrating robust gains over the past several sessions and outperforming its sector peers.

Prism Medico & Pharmacy Ltd, a player in the Non Banking Financial Company (NBFC) sector, reached a significant milestone today by hitting a new 52-week high of Rs.26.12. This marks a continuation of the stock’s robust momentum, reflecting a strong rally over the past week and notable outperformance relative to its sector peers.

Prism Medico & Pharmacy Ltd has surged to a fresh 52-week high of Rs.24.88, marking a significant milestone in its stock performance. This new peak reflects sustained momentum, with the stock outperforming its sector and demonstrating robust gains over recent sessions.

Prism Medico & Pharmacy Ltd, a player in the Non Banking Financial Company (NBFC) sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions amid mixed financial metrics and peer comparisons, prompting a reassessment of its price attractiveness for investors.

Prism Medico & Pharmacy Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Prism Medico, a microcap player in the Non Banking Financial Company (NBFC) sector, has experienced a revision in its market assessment reflecting challenges in its financial health and stock performance. Recent analytical changes highlight concerns over the company’s operational results and market returns, signalling a cautious outlook for investors.

Prism Medico & Pharmacy Ltd is currently experiencing significant selling pressure, with the stock registering only sell orders and no buyers in the queue. This extreme market behaviour signals distress selling, as the company’s shares continue to face downward momentum amid a series of consecutive losses.

Prism Medico & Pharmacy Ltd has encountered significant selling pressure, with the stock registering a sharp decline and exhibiting a complete absence of buyers on the trading day. This distress selling signals heightened market caution surrounding the company’s near-term prospects.

Prism Medico & Pharmacy Ltd has encountered significant selling pressure, with the stock registering a sharp decline of 4.96% today and exhibiting no buying interest. This distress selling comes amid a series of consecutive losses, signalling heightened investor caution in the Non Banking Financial Company (NBFC) sector.

Prism Medico & Pharmacy Ltd is currently experiencing significant selling pressure, with the stock registering only sell orders and no buyers in the queue. This distress selling has resulted in a continuation of losses, reflecting a challenging phase for the company within the Non Banking Financial Company (NBFC) sector.

Prism Medico & Pharmacy Ltd is experiencing severe selling pressure, with the stock registering a lower circuit and an absence of buyers on the trading day. The company’s shares have recorded consecutive losses across multiple time frames, signalling distress selling and a challenging market environment for this Non Banking Financial Company (NBFC).

Prism Medico & Pharmacy, a player in the Non Banking Financial Company (NBFC) sector, reported a flat financial trend for the quarter ending September 2025, marking a shift from its previous positive trajectory. The company’s financial trend score declined to -3 from 7 over the past three months, reflecting a period of subdued operational performance despite a modest rise in profit after tax (PAT) over the last six months.

Prism Medico & Pharmacy, a microcap in the NBFC sector, has experienced a valuation adjustment, now classified as very attractive. Key financial metrics include a PE ratio of 18.90, a Price to Book Value of 0.76, and an ROE of 4.04%, despite challenges in debt servicing and stock performance.

Prism Medico & Pharmacy, a microcap in the NBFC sector, has adjusted its valuation, showcasing a PE ratio of 18.90 and an EV to EBITDA ratio of 11.46. Its price-to-book value of 0.76 indicates favorable asset valuation, despite a year-to-date stock decline of 21.45%.